The degradation pathway for the HBV envelope proteins involves proteolysis prior to degradation via the cytosolic proteasome.
To study the pathway of degradation of the hepatitis B virus (HBV) middle envelope protein (M), human hepatoblastoma cells were transfected with a plasmid that specifies production of M in the absence of other viral proteins. When expressed in HepG2 cells, 90% of M protein was secreted into the culture media within a 24-h period. However, quite surprisingly, 10% of this protein remained cell associated and was only slowly degraded over a 24-48-h period. Treatment with inhibitors of the cytosolic proteasome complex resulted in the accumulation of full-length HBV M protein and M derived HBV-specific polypeptides of 20 and 17 kDa. Treatment with the endoglycosidases PNGase F and Endo H, confirmed that the two species were derived from a similar polypeptide with a N-linked glycan modification. Evidence that this peptide was derived from a proteolytic processing event was determined through the detection of the C-terminal fragment using a C-terminal tagged HA tagged construct. The hypothesis that the 20 and 17 kDa polypeptide species are intermediates of M degradation was reinforced by their detection in cells transfected with vectors specifying M secretion defective mutants that accumulate intracellular M. Moreover, deletion of a putative cleavage sites prevented the detection of the 20 and 17 kDa species, consistent with the notion that they are generated by the action of a cellular protease prior to proteasomal degradation. Thus, these results highlight an important way in which large protein aggregates, such as the HBsAg can be processed for efficient degradation via the proteasomes and allow for proper antigen presentation via the MHC I pathway.
Liu
Yuanjie
Y
Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, PA 18902, USA.
Zhou
Tianlun
T
Simsek
Ender
E
Block
Timothy
T
Mehta
Anand
A
D000595:Amino Acid Sequence; D045744:Cell Line, Tumor; D003600:Cytosol / Q000378:metabolism*; D010450:Endopeptidases / Q000378:metabolism*; D022781:Hepatocytes / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D015151:Immunoblotting; D008954:Models, Biological; D008969:Molecular Sequence Data; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000378:metabolism*
D014759:Viral Envelope Proteins; C114312:middle envelope protein, Hepatitis B virus; D010450:Endopeptidases; D046988:Proteasome Endopeptidase Complex
Nat Rev Drug Discov. 2002 Jan;1(1):65-75
12119611
J Exp Med. 1997 Aug 18;186(4):479-87
9254646
Hepatology. 2005 Apr;41(4):761-70
15726643
Virology. 2002 Jan 5;292(1):44-58
11878907
Methods Mol Med. 2004;95:165-73
14762304
J Immunol. 1996 Sep 1;157(5):1823-6
8757297
J Virol. 2005 Oct;79(20):12914-20
16188993
Cancer Sci. 2006 Aug;97(8):683-8
16863502
Annu Rev Biochem. 2004;73:1019-49
15189166
J Biol Chem. 2004 Nov 5;279(45):46384-92
15319438
J Cell Biol. 1996 Feb;132(3):291-8
8636208
J Virol. 1998 Jan;72(1):778-82
9420286
J Immunol. 2000 Jun 15;164(12 ):6147-57
10843664
Antimicrob Agents Chemother. 2004 Jun;48(6):2085-90
15155204
Carcinogenesis. 2004 Oct;25(10):2023-32
15180947
Bioessays. 2003 Sep;25(9):868-77
12938176
J Gen Virol. 1994 Nov;75 ( Pt 11):3031-9
7964612
Arch Virol Suppl. 1992;4:129-32
1450681
J Virol. 1997 Jul;71(7):5487-94
9188622
Virology. 1995 Aug 20;211(2):535-43
7645257
Nat Cell Biol. 2005 Aug;7(8):766-72
16056268
Genome Biol. 2000;1(2):REVIEWS1013
11178235
EMBO J. 2003 Mar 3;22(5):1036-46
12606569
J Clin Invest. 2002 Dec;110(11):1579-83
12464659
Mol Cell Biol. 2005 Sep;25(17 ):7522-33
16107700
Annu Rev Biochem. 1993;62:65-100
8352598
J Cell Biol. 1990 Sep;111(3):857-66
1697299
Arch Virol. 1997;142(11):2257-67
9672591
J Virol. 1997 Oct;71(10):7387-92
9311817